BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moosavian SA, Sathyapalan T, Jamialahmadi T, Sahebkar A. The Emerging Role of Nanomedicine in the Management of Nonalcoholic Fatty Liver Disease: A State-of-the-Art Review. Bioinorg Chem Appl 2021;2021:4041415. [PMID: 34659388 DOI: 10.1155/2021/4041415] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Jeeyavudeen MS, Khan SKA, Fouda S, Pappachan JM. Management of metabolic-associated fatty liver disease: The diabetology perspective. World J Gastroenterol 2023; 29(1): 126-143 [DOI: 10.3748/wjg.v29.i1.126] [Reference Citation Analysis]
2 Panzarini E, Leporatti S, Tenuzzo BA, Quarta A, Hanafy NAN, Giannelli G, Moliterni C, Vardanyan D, Sbarigia C, Fidaleo M, Tacconi S, Dini L. Therapeutic Effect of Polymeric Nanomicelles Formulation of LY2157299-Galunisertib on CCl(4)-Induced Liver Fibrosis in Rats. J Pers Med 2022;12. [PMID: 36579532 DOI: 10.3390/jpm12111812] [Reference Citation Analysis]
3 Momtazi-Borojeni AA, Banach M, Ruscica M, Sahebkar A. The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition. Expert Rev Clin Pharmacol 2022;:1-10. [PMID: 36193738 DOI: 10.1080/17512433.2022.2132229] [Reference Citation Analysis]
4 Nasiri-Ansari N, Androutsakos T, Flessa CM, Kyrou I, Siasos G, Randeva HS, Kassi E, Papavassiliou AG. Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review. Cells 2022;11:2511. [PMID: 36010588 DOI: 10.3390/cells11162511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mahmoudi A, Moallem SA, Johnston TP, Sahebkar A. Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models. PPAR Res 2022;2022:5805398. [PMID: 35754743 DOI: 10.1155/2022/5805398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Balta S. Atherosclerosis and Non-Alcoholic Fatty Liver Disease. Angiology 2022;:33197221091317. [PMID: 35476909 DOI: 10.1177/00033197221091317] [Reference Citation Analysis]
7 Assadpour S, Shiran MR, Asadi P, Akhtari J, Sahebkar A, de Araujo DR. Harnessing Intranasal Delivery Systems of Sumatriptan for the Treatment of Migraine. BioMed Research International 2022;2022:1-9. [DOI: 10.1155/2022/3692065] [Cited by in F6Publishing: 1] [Reference Citation Analysis]